Skip to content

A program for ALS Care in Europe

A program for ALS Care in Europe - ALS-CarE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON46176
Enrollment
120
Registered
2016-07-06
Start date
2016-11-07
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotropic Lateral Sclerosis (ALS) muscle disease

Interventions

None listed

Sponsors

divisie hersenen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a patient (age > 18 years) must meet all of the following criteria: Possible, Probable, Laboratory Supported Probably and Definite ALS according to the El Escorial Criteria.Caregivers have to be older than 18 years.

Exclusion criteria

Exclusion criteria: Patients who are impaired to the extent that they cannot complete an informed consent process are excluded from participation in the study. Patients who already participate in study 16-273 (NL56989.041.16)

Design outcomes

Primary

MeasureTime frame
Effectiveness of the ALS-healthcare programme for patients and caregivers will be evaluated using QoL, distress and cost effectiveness measures. McGill quality of life questionnaire, the Schedule for the Evaluation of Individual Quality of Life (SeiQoL) and 5Q-5D-5L, and anxiety and depression (Hospital Anxiety and Depression scale). Additionally, for a subset of patients and caregivers an exploratory nested study (N=25) will be conducted which includes detailed quality of life assessments including existential domains, attitudes to end of life, advance directives and decision-making and meaning of life developed by the Munich ALS-CarE partners will be applied.

Secondary

MeasureTime frame
Correlates of QoL, anxiety, depression and caregiver burden with ALS severity which will be measured with ALS-FRS-R, Mitos and Kings staging, Edinburgh Cognitive ALS screen (ECAS), Vital Capacity and Sniff Nasal Inspiratory Pressure (SNIP) (part 3 of the data collection for patients).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)